导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.46% | 3936/4773 |
| 近一周 | -2.51% | 3976/5465 |
| 近一月 | -2.72% | 1845/5421 |
| 近一季 | -2.51% | 1402/5231 |
| 近半年 | -4.50% | 2844/4920 |
| 近一年 | -15.95% | 3788/4394 |
| 近两年 | 29.33% | 2309/2954 |
| 近三年 | 9.80% | 1760/2253 |
| 成立以来 | 43.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.40% 4648/4961 |
8.52% 2585/5312 |
- - |
- - |
| 2025 | 3.21% 3142/4813 |
-6.82% 3401/3635 |
4.12% 857/4076 |
10.82% 3238/4524 |
-4.01% 3376/4813 |
| 2024 | 28.48% 154/3463 |
-4.81% 1769/2808 |
-7.94% 2145/3014 |
42.51% 49/3129 |
2.88% 880/3463 |
| 2023 | 2.96% 297/2656 |
3.77% 1130/2280 |
-3.07% 738/2385 |
7.20% 57/2515 |
-4.51% 1067/2655 |
| 2022 | -24.76% 1254/2207 |
-17.71% 1248/1919 |
1.92% 1401/2016 |
-15.21% 1246/2113 |
5.80% 436/2208 |
| 2021 | -4.79% 959/1822 |
-15.65% 1193/1255 |
6.47% 746/1330 |
4.31% 368/1466 |
1.62% 856/1822 |
| 2020 | 10.59% 835/1250 |
-11.28% 832/1028 |
6.21% 868/1067 |
19.08% 73/1164 |
-1.44% 1107/1184 |
| 2019 | 40.49% 251/1092 |
43.61% 31/754 |
-6.71% 518/804 |
-4.36% 768/850 |
9.64% 215/918 |
| 2018 | -23.55% 288/834 |
- - |
- - |
- - |
-1.41% 13/691 |
| 2017 | -11.08% 540/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.97% 390/605 |
- - |
- - |
- - |
- - |
| 2015 | -29.75% 306/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万菱信中证申万证券行业指数(LOF)A VS. 长安沪深300非周期A(740101) |